SAM
MCRB icon

Shell Asset Management’s Seres Therapeutics MCRB Stock Holding History

Shell Asset Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-413
Closed -$202K – 1476
2020
Q4 		$202K Buy
+413
New +$242K ﹤0.01% 1114

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Shell Asset Management's MCRB Position: Q1 2021 in Review

Shell Asset Management sold out of Seres Therapeutics (MCRB) in Q1 2021, closing a stake of 413 shares — an estimated $202K sold.

Shell Asset Management first reported a position in MCRB in Q4 2020 and held it in 1 quarter. The position peaked at $202K in Q4 2020. 152 funds tracked by Wall St. Rank hold MCRB as of Q1 2021.

  • Shell Asset Management reported no remaining Seres Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Shell Asset Management sold 413 Seres Therapeutics shares in Q1 2021, an estimated $202K.
  • Shell Asset Management first reported a position in Seres Therapeutics in Q4 2020 and held it in 1 quarter.
  • Shell Asset Management's Seres Therapeutics position peaked at $202K in Q4 2020.
  • 152 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2021.

Based on Shell Asset Management's 13F filing for Q1 2021, filed 10 May 2021.